Published 5 days ago • loading... • Updated 4 days ago

Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting

Grit Biotechnology and Myeloid Therapeutics presented new clinical data on TIL and mRNA CAR therapies at the 2025 ASCO Annual Meeting in Chicago from May 30 to June 3, 2025.
These presentations follow ongoing Phase 1 and Phase 2 trials focused on novel in vivo CAR therapies by Myeloid and TIL therapies by Grit Bio to treat advanced solid tumors including hepatocellular carcinoma and cervical cancer.
Myeloid's MT-302 and MT-303 use intravenous mRNA-LNP to reprogram myeloid cells targeting TROP2 and GPC3, while Grit Bio's GT101, GT201, and GT300 are autologous or CRISPR-modified TIL therapies with promising safety and activity profiles.
Daniel Getts, CEO of Myeloid, highlighted that their presentations reflect advancement in applying their unique mRNA-LNP technology to modify immune cells directly within the body, while the company’s CMO emphasized that these treatments are capable of infiltrating solid tumors and reshaping their surrounding environment.
These results validate Myeloid’s platform and Grit Bio’s pipelines, suggesting potential breakthroughs for accessible, tumor-specific immunotherapies that may reduce burdens of traditional treatments and transform solid tumor care.

Insights by Ground AI

Does this summary seem wrong?

14 Articles

All

Left

Center

Right

WREX

+9 Reposted by 9 other sources

Center

Myeloid Therapeutics Unveils First-in-Human In Vivo mRNA CAR Data, Marking a Breakthrough in RNA-Based Immuno-Oncology at the 2025 ASCO Annual Meeting

– MT-302 and MT-303 embody the first clinical applications of in vivo mRNA CAR therapies administered systemically –

4 days ago

Read Full Article

Borger News-Herald

+3 Reposted by 3 other sources

Center

Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting

SHANGHAI, May 29, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three abstracts featuring new clinical data from tumor-infiltrating lymphocytes (TIL) therapies will be presented at the American Society of…

5 days ago·Borger, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year